Adolescent Results Put Pfizer/BioNTech Ahead Of COVID Vaccine Pack, For Now

Hoping For EUA Before Start Of School Year

An EUA would carve out a market advantage, although Moderna should be releasing similar data soon for its COVID-19 vaccine.

Pfizer Inc. and BioNTech SE are positioned for the early lead in the broader market opportunity for vaccinating children against SARS-CoV-2, with strong results for their COVID-19 vaccine, BNT162b2, in adolescents aged 12-15. And if successful, another study in young children that just began dosing participants will fully round out the vaccine’s reach.

The companies said 31 March that topline results from their Phase III study in 2,260 adolescents showed a 100% protection...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip